Insights
-
12 January 2021
Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020
EY’s 2021 M&A Firepower report considered the ups and downs of biopharma M&A in 2020 and the prospects for deal-making in 2021. What lessons have been learned during the Covid-19...
-
11 January 2021
UK Covid-19 vaccine rollout: the dosing schedule debate
Simultaneous to the emergency approval of a second Covid-19 vaccine, UK healthcare regulator the MHRA recommended the second dose for both approved vaccines should be administered up to 12 weeks...
-
5 January 2021
UK rollout of AZ/Oxford Covid-19 vaccine: what you need to know
The UK has approved its second Covid-19 vaccine for emergency use: AZ/Oxford’s candidate. This is welcome news given how serious the Covid-19 epidemic in the UK has become this winter....
-
21 December 2020
Q&A: delivering a billion doses with the UK Vaccines Manufacturing and Innovation Centre
With multiple Covid-19 vaccines close to approval, the spotlight is on the logistics of delivering these vaccines to billions of people globally. Central to the UK’s strategy is to bring...
-
18 December 2020
Q&A: How do you fast-track a vaccine? UCL scientists weigh in
It usually takes around a decade to bring a new vaccine to market, but several Covid-19 candidates have already shown promising results in late-stage trials and one has already received...
-
17 December 2020
New Zealand: a promising destination for trials in a post-Covid-19 world?
Unlike the rest of the world, New Zealand’s speedy and decisive response to Covid-19 has successfully enabled the country’s clinical trials to continue largely unscathed. Allie Nawrat talks to key...
-
16 December 2020
Fraudulent pharmaceuticals: the legacy of anti-counterfeit packaging
As a result of its departure from the EU, the UK is in need of new solutions to protect its supply chains from counterfeit medicines. At the same time, the...
-
14 December 2020
Why is President-elect Joe Biden a good pick for the pharma industry?
Former vice-president Joe Biden has defeated incumbent Donald Trump in the 2020 US Presidential election. A major battleground in the election was healthcare focused around response to the Covid-19 pandemic,...
-
9 December 2020
Allergy issue flagged as Pfizer/BioNTech Covid-19 vaccine rolls out in the UK
Within a day of the UK starting its Covid-19 vaccine roll-out, the MHRA has emphasised that people with a history of significant allergic reactions should not be given Pfizer/BioNTech’s Covid-19...
-
9 December 2020
Gold standard: why are Phase III trials so critical?
Phase III trials represent the final hurdle for many drug approvals, and a key safety net for patients, as highlighted by the current wave of Covid-19 vaccine development programmes. What...